Ourailidis I, Stogbauer F, Zhou Y, Beck S, Romanovsky E, Eckert S
NPJ Precis Oncol. 2025; 9(1):73.
PMID: 40082664
PMC: 11906922.
DOI: 10.1038/s41698-025-00856-2.
Sasaki N, Homme M, Murayama T, Osaki T, Tenma T, An T
Mol Cell. 2024; 85(4):770-786.e7.
PMID: 39706184
PMC: 11888943.
DOI: 10.1016/j.molcel.2024.11.025.
Zhao D, Deshpande R, Wu K, Tyagi A, Sharma S, Wu S
Neoplasia. 2024; 60:101100.
PMID: 39671912
PMC: 11699798.
DOI: 10.1016/j.neo.2024.101100.
Hu Y, Paris S, Sahoo N, Wang Q, Wang Q, Barsoumian H
J Nanobiotechnology. 2024; 22(1):597.
PMID: 39354474
PMC: 11445951.
DOI: 10.1186/s12951-024-02855-0.
He K, Puebla-Osorio N, Barsoumian H, Sezen D, Rafiq Z, Riad T
J Exp Clin Cancer Res. 2024; 43(1):251.
PMID: 39218928
PMC: 11367833.
DOI: 10.1186/s13046-024-03165-x.
Targeted nutritional intervention attenuates experimental lung cancer cachexia.
van de Worp W, Theys J, Wolfs C, Verhaegen F, Schols A, van Helvoort A
J Cachexia Sarcopenia Muscle. 2024; 15(5):1664-1676.
PMID: 38965830
PMC: 11446694.
DOI: 10.1002/jcsm.13520.
miR-200-mediated inactivation of cancer-associated fibroblasts via targeting of NRP2-VEGFR signaling attenuates lung cancer invasion and metastasis.
Cheon I, Lee S, Oh S, Ahn Y
Mol Ther Nucleic Acids. 2024; 35(2):102194.
PMID: 38766528
PMC: 11101731.
DOI: 10.1016/j.omtn.2024.102194.
Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.
Tan X, Wang S, Xiao G, Wu C, Liu X, Zhou B
J Clin Invest. 2024; 134(12).
PMID: 38662435
PMC: 11178546.
DOI: 10.1172/JCI176355.
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors.
Rodriguez B, Huang J, Gibson L, Fradette J, Chen H, Koyano K
Mol Cancer Ther. 2024; 23(8):1144-1158.
PMID: 38648067
PMC: 11293989.
DOI: 10.1158/1535-7163.MCT-23-0866.
Unleashing the Potential of 1,3-Diketone Analogues as Selective LH2 Inhibitors.
Lee J, Guo H, Wang S, Maghsoud Y, Vazquez-Montelongo E, Jing Z
ACS Med Chem Lett. 2023; 14(10):1396-1403.
PMID: 37849534
PMC: 10577891.
DOI: 10.1021/acsmedchemlett.3c00305.
Human milk EV-miRNAs: a novel biomarker for air pollution exposure during pregnancy.
Holzhausen E, Kupsco A, Chalifour B, Patterson W, Schmidt K, Mokhtari P
Environ Res Health. 2023; 1(3):035002.
PMID: 37692372
PMC: 10486183.
DOI: 10.1088/2752-5309/ace075.
A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment.
Wei C, Huang L, Kreh B, Liu X, Tyutyunyk-Massey L, Kawakami M
Sci Rep. 2023; 13(1):14907.
PMID: 37689790
PMC: 10492813.
DOI: 10.1038/s41598-023-41690-5.
MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy.
Song Y, Kelava L, Kiss I
Int J Mol Sci. 2023; 24(17).
PMID: 37686110
PMC: 10487838.
DOI: 10.3390/ijms241713302.
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
Konen J, Rodriguez B, Wu H, Fradette J, Gibson L, Diao L
J Clin Invest. 2023; 133(17).
PMID: 37655662
PMC: 10471170.
DOI: 10.1172/JCI163128.
Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention.
Zhang Q, Pan J, Xiong D, Zheng J, McPherson K, Lee S
Front Immunol. 2023; 14:1166951.
PMID: 37520581
PMC: 10372486.
DOI: 10.3389/fimmu.2023.1166951.
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Rodriguez B, Chen L, Li Y, Miao S, Peng D, Fradette J
Front Immunol. 2023; 14:1161869.
PMID: 37449205
PMC: 10336223.
DOI: 10.3389/fimmu.2023.1161869.
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.
Xiao G, Tan X, Rodriguez B, Gibbons D, Wang S, Wu C
Proc Natl Acad Sci U S A. 2023; 120(28):e2220276120.
PMID: 37406091
PMC: 10334751.
DOI: 10.1073/pnas.2220276120.
ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis.
Perez-Oquendo M, Manshouri R, Tian Y, Fradette J, Rodriguez B, Kundu S
Mol Cancer Res. 2023; 21(8):779-794.
PMID: 37255406
PMC: 10390859.
DOI: 10.1158/1541-7786.MCR-22-0503.
A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma.
Garinet S, Didelot A, Marisa L, Beinse G, Sroussi M, Le Pimpec-Barthes F
J Transl Med. 2023; 21(1):324.
PMID: 37189151
PMC: 10184345.
DOI: 10.1186/s12967-023-04086-7.
Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer.
Bychkov I, Topchu I, Makhov P, Kudinov A, Patel J, Boumber Y
Cancers (Basel). 2023; 15(9).
PMID: 37173995
PMC: 10177017.
DOI: 10.3390/cancers15092529.